Episode Details

Trump’s new tariff plan targets overseas generic drugs, starting at 100% in August 2028 and soaring to 200% by 2029, aiming to lure pharma companies back to U.S. soil. But with most generics sourced from India and reliant on Chinese ingredients, the move risks supply chain chaos. Manufacturers, already operating on razor-thin margins, face tough choices: absorb costs, raise prices, invest in U.S. plants, or exit the market. Experts warn this blunt economic pressure could trigger shortages or force patients toward pricier brand-name drugs — and question whether tariffs alone can build a resilient domestic supply without a clear investment roadmap. It’s not the first time Trump has used tariffs to push industry reshoring, with past moves already prompting some companies to invest in U.S. factories — part of a broader push to revive American manufacturing.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/4bc987b3f11e9fea